



United States Patent and Trademark Office

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231 www.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/863,786

05/23/2001

Ronnie Palmgren

PU-0124

CONFIRMATION NO. 2351

FORMALITIES LETTER

OC000000006338653*

Amersham Pharmacia Biotech, Inc. 800 Centennial Avenue

Piscataway, NJ 08855

Date Mailed: 07/25/2001



OTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given TWO MONTHS from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- The balance due by applicant is \$ 130.

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

10/01/2001 HVUONG1 00000021 500588 09863786

01 FC:105

130.00 CH

BEST AVAILABLE COPY

يندو				# > Ect					
	Response To N Filing Dat	Docket No. PU-0124							
In Re	e Application Of: R.	Palmgren, et al.							
	Serial No. 09/863,786	Filing Date May 23, 2001	Examiner To be assigned	Group Art Unit					
Inver	Peptide Frag	mentation							
Ž.		TO THE ASSISTANT COM	MISSIONER FOR PATENTS:						
ENT & TR.	3DEMARRE	Box Mis	ssing Parts						
	s a response to the N uly 25, 2001 Date	Notice to File Missing Parts of A	pplication - Filing Date Granted (PT	O-1533) mailed on					
Enclos	sed herewith for filing	g are the following:							
\boxtimes	A copy of the Notice	e to File Missing Parts of Applica	ation - Filing Date Granted (PTO-15	33). (REQUIRED)					
	An oath or declara		R 1.63, including residence inform						
\boxtimes	A properly signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date.								
	An oath or declaration in compliance with 37 CFR 1.63 listing the names of all inventors and signed by the omitted inventor(s), identifying this application by the above Application Number and Filing Date.								
	A verified English translation of the non-English language application papers as originally filed. It is requested that this translation be used as the copy for examination purposes in the United States Patent and Trademark Office.								
\boxtimes	Other (list):								
	request for a correct	tal letter for charging purposes ed filing receipt ne filing receipt having a mailing	date of July 25, 2001						

Response To I Filing Da	Docket No. PU-0124									
In Re Application Of: R. Palmgren, et al.										
Serial No. 09/863,786	Filing Date May 23, 2001	Examiner To be assigned	Group Art Unit 1645							
Invention: Peptide Fra	gmentation									
TO THE ASSISTANT COMMISSIONER FOR PATENTS:										
		sing Parts								
	lication fees as calculated below:									
☐ Utility applica	tion filing fee									
☐ Design applic	ation filing fee	,								
☐ Total number	of independent claims =									
☐ Total number	of claims =									
☐ Multiple depe	ndent claims									
Surcharge for Sur	Surcharge for late payment of filing fee and/or late filing of original declaration or oath \$130.00									
Petition and fee for filing by other than all the inventors or a person not the inventor										
☐ Fee for processing an application filed with a non-English language specification										
☐ Fee for processing and retention of application										
		Total completion of appli	cation fees\$130.00							
above-identified Notice to	r the provisions of 37 CFR 1. File Missing Parts of Application time extension is required, please	 The requested extension is 	as follows (check time period							
☐ One month	☐ Two months ☐ The	ree months 🔲 Four month	hs 🔲 Five months							
from:	Date	until:								
		Total time ext	ension fees\$0.00_							
		To	tal fees due \$130.00							

Response To Notice To File Missing Parts Of Application Filing Date Granted (PTO-1533) (Large Entity)

Docket No. PU-0124

In Re Application Of: R. Palmgren, et al.

Serial No. 09/863,786

Filing Date May 23, 2001

Examiner To be assigned Group Art Unit

1645

Invention:

Peptide Fragmentation

TO THE ASSISTANT COMMISSIONER FOR PATENTS:

Box Missing Parts

The fee of

\$130.00

is to be paid as follows:

- A check in the amount of the fee is enclosed.
- The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account No. 500-588 A duplicate copy of this sheet is enclosed.
- If an additional extension of time is required, please consider this a petition therefor and charge any additional fees which may be required to Deposit Account No. 500-588 A duplicate copy of this sheet is enclosed.

Dated: September 24, 2001

Robert F. Chisholm Amersham Pharmacia Biotech, Inc. 800 Centennial Avenue Piscataway, New Jersey 08855

(732) 980-2930 Reg. No.: 39,939 I certify that this document and fee is being deposited with the U.S. Postal Service as on September 24, 2001 first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Melissa Leck

Typed or Printed Name of Person Mailing Correspondence

CC:





CERTIFICATE OF MAILING

I her specified that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to the: Assistant Commissioner for Patents Washington, D.C. 20231.

Melissa Leck
Type or print name

Signature

September 24, 2001

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

R. Palmgren, et al.

Group Art Unit:

1645

Serial No.:

09/863,786

Examiner:

To be assigned

Filing Date:

May 23, 2001

Title:

Peptide Fragmentation

REQUEST FOR A CORRECTED FILING RECEIPT

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, D.C. 20231

Sir:

Please furnish the undersigned with a corrected filing receipt for the above-identified application. The correction required is as follows:

In the "Applicant(s)" section, please delete the Applicant Eva Wiksell.

Applicants authorize the Commissioner to charge any additional fees that may be necessary, or credit any excess fees paid, to Applicant's Deposit Account Number 500-588. Enclosed is a marked up copy of the Filing Receipt having a mailing date of July 25, 2001. Any questions can be referred to the undersigned.

Amersham Pharmacia Biotech, Inc.

P.O. Box 1327

800 Centennial Avenue

Piscataway, New Jersey 08855-1327

(732)980-2930 (voice)

(732)457-8463 (facsimile)

Respectfully submitted,

Robert F. Chisholm

Reg. No. 39,939

\USPISBT_1\VOL1\DEPT\Law_Dept\IP Dept\Request for Corrected Filing Receipt\Request for Corrected Filing Receipt-PU0124.dot



AND TRADEMARK OFFICE United States Pater

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231 www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/863,786	05/23/2001	1645	710	PU-0124	19	20	3

CONFIRMATION NO. 2351

FILING RECEIPT

OC000000006338652

Amersham Pharmacia Biotech, Inc. 800 Centennial Avenue Piscataway, NJ 08855

Date Mailed: 07/25/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Ronnie Palmgren, Stockholm, SWEDEN; Jean-Luc Maloisel, Enebyberg, SWEDEN; Eva Wiksell, Uppsala, SWEDEN; Maria Liminga, Uppsala, SWEDEN; Thomas Woods Keough, Cincinnati, OH; Robert Scott Youngquist, Mason, OH;

Domestic Priority data as claimed by applicant

JUL 3 0 2001 ROYAL N. RONNING, JR.

Foreign Applications

If Required, Foreign Filing License Granted 07/24/2001

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

Title

Peptide fragmentation

Preliminary Class

Data entry by : QUINTEROS, KARLA

Team : OIPE

Date: 07/25/2001

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 500 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231